Pharmaceuticals · NYSE: ZTS
Zoetis earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 11 Feb 2027
Latest: Q3 2026
Zoetis slowed U.S. dermatology share loss to 4 points through targeted promotions and advanced long-acting Cytopoint and Simparica Duo toward approval, while Livestock and Diagnostics offset pet-owner weakness.
Companion Animal stayed under pressure from higher vet costs, fewer clinic visits and new competitors in dermatology and parasiticides. Zoetis answered with promotions that cut U.S. dermatology share loss from 7 to 4 points a quarter. Livestock grew on cattle, fish and vaccines, and Diagnostics grew through the VitalRADS and Veterinary Pathology Group acquisitions. Lenivia and Portela launched in the EU, Canada and Great Britain.
Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗Official transcript (PDF) ↗
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.3B * |
| Q1 2025 | $2.2B |
| Q2 2025 | $2.5B |
| Q3 2025 | $2.4B |
| Q4 2025 | $2.4B * |
| Q1 2026 | $2.3B |
| Q2 2026 | $2.5B |
| Q3 2026 | $2.4B |
Data
| Q1 2025 | $1.34 |
| Q2 2025 | $1.63 |
| Q3 2025 | $1.63 |
| Q1 2026 | $1.42 |
| Q2 2026 | $1.65 |
| Q3 2026 | $1.44 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | $689.0M |
| Q1 2025 | $337.0M |
| Q2 2025 | $459.0M |
| Q3 2025 | $798.0M |
| Q4 2025 | $689.0M |
| Q1 2026 | $291.0M |
| Q2 2026 | $538.0M |
| Q3 2026 | $717.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3Bd | $2.2B | $2.5B | $2.4B | $2.4Bd | $2.3B | $2.5B | $2.4B |
| Net income | $581.0Md | $602.0M | $726.0M | $721.0M | $624.0Md | $601.0M | $691.0M | $591.0M |
| Diluted EPS | — | $1.34 | $1.63 | $1.63 | — | $1.42 | $1.65 | $1.44 |
| Operating cash flow | $905.0Md | $515.0M | $605.0Md | $936.0Md | $848.0Md | $401.0M | $655.0Md | $824.0Md |
| Capital expenditure | $216.0Md | $178.0M | $146.0Md | $138.0Md | $159.0Md | $110.0M | $117.0Md | $107.0Md |
| Free cash flow | $689.0M | $337.0M | $459.0M | $798.0M | $689.0M | $291.0M | $538.0M | $717.0M |
| R&D expense | $186.0Md | $162.0M | $166.0M | $175.0M | $195.0Md | $180.0M | $173.0M | $174.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 5 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 6 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 7 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 12 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 4 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 5 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 6 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 13 Feb 202510-K for the period ended 31 Dec 2024SEC ↗